A case of alemtuzumab-induced thyroid disease with a fluctuating course

Abstract

Alemtuzumab (ALZ) is a humanized monoclonal antibody licensed for the treatment of relapsing–remitting multiple sclerosis (RRMS). One of its common side effects is autoimmune thyroid disease, most commonly Graves' disease (GD). Here, we present a case of a 39-year-old female that was on ALZ for the treatment of RRMS. After two cycles, she developed GD, which later converted to severe hypothyroidism.

Keywords

• alemtuzumab
• multiple sclerosis
• thyroid disease